Skip to main content
Clinical Trials/IRCT138706171100N2
IRCT138706171100N2
Completed
Phase 2

A randomized clinical trial for the evaluation of the efficacy of 30 mCi versus 100 mCi, 131I for ablation of residual thyroid tissue

Vice chancellor for research, Tehran University of Medical Sciences0 sites341 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Diffrentiated Thyroid Cancer.
Sponsor
Vice chancellor for research, Tehran University of Medical Sciences
Enrollment
341
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Tehran University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients with differentiated thyroid carcinoma (DTC): without any history of ablation therapy; with no palpable mass in the neck; with no evidence of capsular; vascular or lymph node invasion. Exclusion criteria: Any area of I\-131 uptake in post\-treatment whole body scan; Failing to follow the patients.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials